CAS Number58579-51-4
Synonyms6,7-Dichlor-1,5-dihydroimidazo[2,1-b]chinazolin-2(3H)-onhydrochlorid; imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride; 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one hydrochloride (1:1); 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one hydrochloride; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one,hydrochloride; MFCD01720337; Anagrelide Hydrochloride; Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-5,10-dihydro-, hydrochloride (1:1); 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one chlorhydrate; Anagrelide (hydrochloride)
Molecular FormulaC10H8O1N3Cl3
Molecular Weight292.55
Purity98.00%
Density1.77g/cm3
Boiling Point376.5ºC at 760 mmHg
Melting Point>280ºC
Appearanceoff-white powder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 58579-51-4 |
| Catalog No. | 2A-9045027 |
| Chinese Name | 盐酸阿那格雷 |
| Synonyms | 6,7-Dichlor-1,5-dihydroimidazo[2,1-b]chinazolin-2(3H)-onhydrochlorid; imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride; 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one hydrochloride (1:1); 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one hydrochloride; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one,hydrochloride; MFCD01720337; Anagrelide Hydrochloride; Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-5,10-dihydro-, hydrochloride (1:1); 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one chlorhydrate; Anagrelide (hydrochloride) |
| Molecular Formula | C10H8O1N3Cl3 |
| Molecular Weight | 292.55 |
| Purity | 98.00 |
| Density | 1.77g/cm3 |
| Boiling Point | 376.5ºC at 760 mmHg |
| Melting Point | >280ºC |
| Appearance | off-white powder |
| Storage Condition | Desiccate at +4°C |
| Application | Anagrelide (BL4162A) hydrochloride is effective against thrombocythemia. |
| HTC | 2933990090 |
| PubChem ID | 537666 |
| MDL Number | MFCD01720337 |
| SMILES | [H+].[Cl-].Clc1ccc2NC3=NC(=O)CN3Cc2c1Cl |
| InChI | InChI=1S/C10H7Cl2N3O.ClH/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7;/h1-2H,3-4H2,(H,13,14,16);1H |
| InChI Key | InChIKey=TVWRQCIPWUCNMI-UHFFFAOYSA-N |
| MSDS | msds/45027_1_58579_51_4.pdf |
| Bioactivity | Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.Target: PDEAnagrelide hydrochloride is an oral imidazoquinazoline agent that has been shown to reduce elevated platelet counts and the risk of thrombosis in patients with thrombocythaemia in various myeloproliferative disorders (MPD). It is currently approved by the FDA as oral treatment for essential thrombocythaemia (ET) and thrombocythaemia associated with polycythaemia vera (PV). Anagrelide is known to inhibit platelet cyclic adenosine monophosphate (cAMP) phosphodiesterase at concentrations that exceed those achieved at doses used to treat ET. Anagrelide is extensively metabolised in the liver and its metabolites are primarily excreted in the urine [1]. Anagrelide is an established platelet-reducing drug. Studies have also investigated the effects of anagrelide on platelets, indicating that platelet function is as important as platelet counts in ET [2]. Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Inflammation/Immunology References [1]. Pescatore, S.L. and C. Lindley, Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother, 2000. 1(3): p. 537-46. [2]. Petrides, P.E., Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost, 2006. 32(4 Pt 2): p. 399-408. Chemical & Physical Properties Density 1.77g/cm3 Boiling Point 376.5ºC at 760 mmHg Melting Point >280ºC Molecular Formula C10H8Cl3N3O Molecular Weight 292.549 Flash Point 181.5ºC Exact Mass 290.973297 PSA 44.70000 LogP 2.43060 Storage condition Desiccate at +4°C |
| Use of | Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.Target: PDEAnagrelide hydrochloride is an oral imidazoquinazoline agent that has been shown to reduce elevated platelet counts and the risk of thrombosis in patients with thrombocythaemia in various myeloproliferative disorders (MPD). It is currently approved by the FDA as oral treatment for essential thrombocythaemia (ET) and thrombocythaemia associated with polycythaemia vera (PV). Anagrelide is known to inhibit platelet cyclic adenosine monophosphate (cAMP) phosphodiesterase at concentrations that exceed those achieved at doses used to treat ET. Anagrelide is extensively metabolised in the liver and its metabolites are primarily excreted in the urine [1]. Anagrelide is an established platelet-reducing drug. Studies have also investigated the effects of anagrelide on platelets, indicating that platelet function is as important as platelet counts in ET [2]. Properties Name anagrelide hydrochloride Synonym More Synonyms Anagrelide HCl Biological Activity Description Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.Target: PDEAnagrelide hydrochloride is an oral imidazoquinazoline agent that has been shown to reduce elevated platelet counts and the risk of thrombosis in patients with thrombocythaemia in various myeloproliferative disorders (MPD). It is currently approved by the FDA as oral treatment for essential thrombocythaemia (ET) and thrombocythaemia associated with polycythaemia vera (PV). Anagrelide is known to inhibit platelet cyclic adenosine monophosphate (cAMP) phosphodiesterase at concentrations that exceed those achieved at doses used to treat ET. Anagrelide is extensively metabolised in the liver and its metabolites are primarily excreted in the urine [1]. Anagrelide is an established platelet-reducing drug. Studies have also investigated the effects of anagrelide on platelets, indicating that platelet function is as important as platelet counts in ET [2]. Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Inflammation/Immunology References [1]. Pescatore, S.L. and C. Lindley, Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother, 2000. 1(3): p. 537-46. [2]. Petrides, P.E., Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost, 2006. 32(4 Pt 2): p. 399-408. Chemical & Physical Properties Exact Mass 290.973297 PSA 44.70000 LogP 2.43060 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Rebaudioside A | 58543-16-1 | 2A-9045016 |
| Schisantherin A | 58546-56-8 | 2A-9045018 |
| Carboprost tromethamine | 58551-69-2 | 2A-9045019 |
| 2,7-Dibromonaphthalene | 58556-75-5 | 2A-9045021 |
| Tyrosylglycyl-glycyl-phenylalanyl-methionine | 58569-55-4 | 2A-9045023 |
| 5-Amino-1-hydroxy-2-naphthalenesulfonic acid | 58596-07-9 | 2A-9045034 |
| L-beta-Homoalanine hydrochloride | 58610-41-6 | 2A-9045036 |
| 3-Chloro-4-hydroxybenzeneacetonitrile | 58622-59-6 | 2A-9045037 |
| Bis(isopropylcyclopentadienyl)zirconium dichloride | 58628-40-3 | 2A-9045039 |
| Cyclopropyl isocyanide | 58644-53-4 | 2A-9045041 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS